文献速递临床微生物质量管理与危急值

四种商品化药敏系统及纸片扩散法与参考肉汤微量稀释法的基准比对:革兰阴性菌评估

Benchmarking four commercial antimicrobial susceptibility testing systems and disk diffusion to reference broth microdilution in the assessment of gram-negative bacterial isolates.
PubMed 文献 · J Clin Microbiol · 2026-09-09

该研究用参考肉汤微量稀释法(BMD)比对纸片扩散法(DD)及Selux、MicroScan、Phoenix、Vitek 2四种商品化药敏系统,共评估372株肠杆菌目和铜绿假单胞菌临床分离株。肠杆菌目中出现最高非常重大误差为Vitek 2检测头孢吡肟(29.0%)和DD检测厄他培南(9.1%);多种药物-系统组合基本一致性低于90%。铜绿假单胞菌中Selux检测庆大霉素(87.2%)、妥布霉素(86.6%)及Phoenix检测环丙沙星(88.4%)基本一致性低于90%。

要点

  • Vitek 2检测肠杆菌目头孢吡肟非常重大误差达29.0%,需警惕。
  • 肠杆菌目中多个药物-系统组合基本一致性低于90%,包括Vitek 2头孢吡肟76.8%。
  • 氨苄西林、阿莫西林-克拉维酸、头孢他啶-阿维巴坦、厄他培南和甲氧苄啶-磺胺甲噁唑在所有商品化系统中偏差较低。

核心结论

  • 多种药物-菌种组合的性能低于监管机构和临床实验室通常要求的标准,且缺陷因商品化平台和纸片扩散法而异。

研究设计与样本

  • 研究纳入280株临床分离株和100株来自美国CDC耐药菌株库的分离株,包括肠杆菌目和铜绿假单胞菌,计划用纸片扩散法及Selux、MicroScan、Phoenix、Vitek 2四种商品化药敏系统测试,并与参考肉汤微量稀释法比较,最终评估372株分离株。

主要发现

  • 肠杆菌目中,非常重大误差频率最高为Vitek 2检测头孢吡肟(29.0%)和纸片扩散法检测厄他培南(9.1%)。
  • 肠杆菌目中基本一致性低于90%的组合包括:MicroScan检测氨曲南(86.4%)、Vitek 2检测氨曲南(88.9%)、Selux检测头孢吡肟(86.3%)、Vitek 2检测头孢吡肟(76.8%)、Vitek 2检测头孢他啶(89.9%)、MicroScan检测左氧氟沙星(83.4%)。
  • 铜绿假单胞菌中基本一致性低于90%的组合包括:Selux检测庆大霉素(87.2%)、Selux检测妥布霉素(86.6%)、Phoenix检测环丙沙星(88.4%)。
  • 在所有自动化商品化药敏系统中偏差较低的抗菌药物包括氨苄西林、阿莫西林-克拉维酸、头孢他啶-阿维巴坦、厄他培南和甲氧苄啶-磺胺甲噁唑。

临床怎么用

  • 当头孢吡肟经Vitek 2报告为肠杆菌目结果时需谨慎复核,因其非常重大误差频率达29.0%。
  • 对基本一致性低于90%的药物-系统组合,实验室应考虑进一步验证或采取缓解策略以防报告错误结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Commercial antimicrobial susceptibility testing (AST) systems for gram-negative bacteria provide operational advantages over reference broth microdilution (BMD) testing, but the results produced by commercial AST systems might not be as accurate as the reference method. Assessing and comparing the performance of AST systems can be informative for clinical microbiology practice. In total, 280 clinical isolates and 100 isolates from the U.S. Centers for Disease Control and Prevention Antimicrobial Resistance Isolate Bank, including Enterobacterales and Pseudomonas aeruginosa, were intended to be tested using disk diffusion (DD) and automated commercial AST systems, such as Selux AST System (Selux Diagnostics), MicroScan (Beckman Coulter), Phoenix (Becton, Dickinson and Company), and Vitek 2 (bioMérieux). These results were compared to BMD as the reference standard. In total, 372 isolates were assessed. For Enterobacterales, the greatest frequency of very major errors was identified with cefepime by Vitek 2 (29.0%) and ertapenem by DD (9.1%); essential agreement less than 90% was identified with the following combinations: aztreonam by MicroScan (86.4%), aztreonam by Vitek 2 (88.9%), cefepime by Selux (86.3%), cefepime by Vitek 2 (76.8%), ceftazidime by Vitek 2 (89.9%), and levofloxacin by MicroScan (83.4%). For P. aeruginosa, essential agreement less than 90% was identified with the following combinations: gentamicin by Selux (87.2%), tobramycin by Selux (86.6%), and ciprofloxacin by Phoenix (88.4%). Overall, antimicrobials that had low demonstrable bias across all automated commercial AST systems included ampicillin, amoxicillin-clavulanate, ceftazidime-avibactam, ertapenem, and trimethoprim-sulfamethoxazole. Comparing commercial testing systems head-to-head against a reference standard provides insight into the strengths and weaknesses of the performance of these test systems, and these insights can subsequently inform local decisions regarding further investigations and potential operational mitigation strategies.IMPORTANCEThis study assessed and compared the performance of multiple commercial antimicrobial susceptibility testing (AST) systems and disk diffusion methods. The accuracy of determining minimum inhibitory concentrations or zone diameters of antimicrobials and the associated interpretive categories were studied for 372 isolates of Enterobacterales and Pseudomonas aeruginosa. Performance of the evaluated systems revealed that multiple antimicrobial-organism combinations were below the standards typically required by regulatory agencies and clinical laboratories. These deficiencies varied across the commercial platforms and disk diffusion methods, highlighting the importance of benchmarking studies that compare the performance using identical isolates. These identified performance weaknesses may warrant further study and/or the implementation of mitigation strategies in clinical laboratory operations to prevent the reporting of errant results.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Rhoads DD, Sherman J, Chen F, et al. Benchmarking four commercial antimicrobial susceptibility testing systems and disk diffusion to reference broth microdilution in the assessment of gram-negative bacterial isolates. J Clin Microbiol. 2026. PMID: 42714132. doi:10.1128/jcm.00502-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。